Healthcare Services

Glaucoma Market Outlook 2026–2030 Exploring New Business Opportunities

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Glaucoma Market Expected To Change Between 2026 And 2030?

The glaucoma market has experienced robust expansion in recent years. It is forecast to increase from $8.2 billion in 2025 to $8.65 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.5%. The historical growth of this market is attributable to factors like an aging population, increased prevalence of eye diseases, advancements in ophthalmic diagnostics, early adoption of drug therapy, and the proliferation of eye clinics.

The glaucoma market is projected to experience robust expansion in the coming years, with its valuation set to reach $10.62 billion by 2030, driven by a compound annual growth rate (CAGR) of 5.3%. This anticipated growth during the forecast period is primarily due to factors such as technological advancements in imaging, the proliferation of surgical innovations, digital eye health monitoring, proactive early detection initiatives, and increasing investments in ophthalmology. Key trends shaping this period encompass the rising adoption of early diagnostic screening, a greater reliance on combination drug therapies, the growth of minimally invasive glaucoma surgery, the broadening scope of home-based eye monitoring, and enhanced patient awareness programs.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20820&type=smp

What Drivers Are Expected To Influence The Glaucoma Market During The Forecast Period?

An increasing incidence of chronic eye ailments is anticipated to drive expansion in the glaucoma market in the future. These conditions are persistent disorders impacting the eyes, frequently resulting in enduring vision problems or discomfort and necessitating continuous care or therapy. The rise in chronic eye conditions is attributed to factors such as an aging demographic, extended screen exposure, lifestyle choices, and a greater occurrence of illnesses like diabetes and hypertension. Treating glaucoma becomes essential for these chronic eye issues to reduce pressure within the eye, avert additional harm to the optic nerve, and maintain sight, given that untreated glaucoma may cause permanent blindness. For example, data from December 2024 by the National Health Service (NHS), the UK’s publicly funded healthcare system, indicated that more than 2 million individuals in the UK were experiencing sight loss in 2024. Moreover, projections indicate that the population experiencing sight loss will grow by 27%, reaching around 2.8 million by 2035. Consequently, the growing occurrence of chronic eye diseases is a key factor propelling the glaucoma market.

How Is The Glaucoma Market Structured Across Different Segments?

The glaucoma market covered in this report is segmented –

1) By Disease Type: Open Angle Glaucoma, Angle Closure Glaucoma, Other Disease Types

2) By Diagnosis: Tonometry, Ophthalmoscopy, Perimetry, Gonioscopy

3) By Drug Class: Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, Other Drug Classes

4) By Administration: Oral, Injections, Intravitreal, Other Administrations

5) By End-User: Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG), Secondary Open Angle Glaucoma

2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma, Secondary Angle Closure Glaucoma

3) By Other Disease Types: Normal-Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma, Congenital Glaucoma

Which Upcoming Trends Are Expected To Influence The Glaucoma Market?

Leading companies in the glaucoma market are concentrating on creating novel treatments, such as Rho-kinase (ROCK) inhibitors. These inhibitors provide a two-fold mechanism, lowering intraocular pressure through both improved aqueous humor drainage and the relaxation of trabecular meshwork cells, proving effective in glaucoma management. Rho-kinase (ROCK) inhibitors represent a category of medications that specifically target and inhibit the function of Rho-kinase enzymes, which control cell contraction and are used in glaucoma treatment to decrease intraocular pressure. As an illustration, in July 2023, Santen Pharmaceutical Co. Ltd., an eye care products firm based in Japan, introduced Roclanda in the UK. Roclanda is a fixed-dose combination (FDC) composed of latanoprost and netarsudil, an innovative Rho-kinase (ROCK) inhibitor, designed to effectively lower intraocular pressure (IOP) by addressing trabecular meshwork dysfunction. This medication is prescribed for adult patients diagnosed with primary open-angle glaucoma or ocular hypertension where sufficient IOP reduction has not been achieved through monotherapy with a prostaglandin or netarsudil. The European debut of Roclanda signifies the first new class of glaucoma medication to emerge in 25 years, representing a significant advancement in therapy. Through the combination of netarsudil and latanoprost, Roclanda operates synergistically to enhance outflow via both trabecular (conventional) and uveoscleral (unconventional) pathways, thus offering a holistic strategy for controlling elevated IOP.

Which Major Players Dominate The Glaucoma Market?

Major companies operating in the glaucoma market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Nidek Co. Ltd., Haag-Streit AG

Read the full glaucoma market report here:

https://www.thebusinessresearchcompany.com/report/glaucoma-global-market-report

Which Region Is Forecast To Lead The Glaucoma Market In Terms Of Market Size?

North America was the largest region in the glaucoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glaucoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Glaucoma Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20820&type=smp

Browse Through More Reports Similar to the Global Glaucoma Market 2026, By The Business Research Company

Periodontal Global Market Report

https://www.thebusinessresearchcompany.com/report/periodontal-global-market-report

Cotton Ginning Machinery Global Market Report

https://www.thebusinessresearchcompany.com/report/cotton-ginning-machinery-global-market-report

Oral Care Global Market Report

https://www.thebusinessresearchcompany.com/report/oral-care-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795